Quantitative serum hepatitis B surface antigen (HBsAg) assay validation for U.S. patient testing
Telemedicine Consult - Dr. Gish
Schedule Telemedicine Consult with Dr. Gish Powered byTelemed2U
Powered byTelemed2U

Quantitative serum hepatitis B surface antigen (HBsAg) assay validation for U.S. patient testing

Published data indicate that HBsAg quantification may be useful to determine HBV disease status, help predict disease progression, and evaluate antiviral treatment response.  Quantitative HBsAg assays are used in select U.S. institutions as research tools and overseas for patient testing.  The Hepatitis B Foundation and expert opinion have advocated for the availability of quantitative HBsAg testing in the U.S.   In early 2017, Quest Diagnostics Infectious Diseases (QDID)   validated a quantitative serum HBsAg laboratory developed test (LDT) for U.S. patient testing.

View PPT Deck


Metadata